|
|||||
|
|
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia |
|
| Authors: | John M. Kane Arthur Rifkin Frederic Quitkin Devdutt Nayak Kishore Saraf Jorge R. Ramos-Lorenzi Donald F. Klein Edward J. Sachar |
| Affiliation: | 1. John M. Kane, M.D., is Director, Psychiatric Research, Long Island JewishHillside Medical Center, USA;2. Devdutt Nayak, M.D. and Kishore Saraf, M.D., are Research Psychiatrists and Jorge R. Ramos-Lorenzi, M.D., is Director Aftercare Clinic, USA;3. Arthur Rifkin, M.D., is Director, Comprehensive Treatment Program, Department of Psychiatry, Mount Sinai Medical Center, USA;4. Frederick Quitkin, M.D., is Director, Depression Evaluation Service, New York State Psychiatric Institute, USA;5. Donald F. Klein, M.D., is Director Research, New York State Psychiatric Institute, USA;6. Edward J. Sachar, M.D., is Director, New York State Psychiatric Institute and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, USA |
| Abstract: | To test the clinical efficacy of low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly), we carried out two separate experiments: (1) an open trial in 57 schizophrenic outpatients, lasting 6 months; (2) a double-blind, placebo-controlled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6-month open trial. The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum. |
| Keywords: | Fluphenazine decanoate minimal dosage outcome schizophrenia |
| 本文献已被 ScienceDirect 等数据库收录！ | |